Dendritic Cells Cause Bone Lesions in a New Mouse Model of Histiocytosis

PLoS One. 2015 Aug 6;10(8):e0133917. doi: 10.1371/journal.pone.0133917. eCollection 2015.

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease caused by the clonal accumulation of dendritic Langerhans cells, which is often accompanied by osteolytic lesions. It has been reported that osteoclast-like cells play a major role in the pathogenic bone destruction seen in patients with LCH and these cells are postulated to originate from the fusion of DCs. However, due to the lack of reliable animal models the pathogenesis of LCH is still poorly understood. In this study, we have established a mouse model of histiocytosis- recapitulating human disease for osteolytic lesions seen in LCH patients. At 12 weeks after birth, severe bone lesions were observed in our multisystem histiocytosis (Mushi) model, when CD8α conventional dendritic cells (DCs) are transformed (MuTuDC) and accumulate. Most importantly, our study demonstrates that bone loss in LCH can be accounted for the transdifferentiation of MuTuDCs into functional osteoclasts both in vivo and in vitro. Moreover, we have shown that injected MuTuDCs reverse the osteopetrotic phenotype of oc/oc mice in vivo. In conclusion, our results support a crucial role of DCs in bone lesions in histiocytosis patients. Furthermore, our new model of LCH based on adoptive transfer of MuTuDC lines, leading to bone lesions within 1-2 weeks, will be an important tool for investigating the pathophysiology of this disease and ultimately for evaluating the potential of anti-resorptive drugs for the treatment of bone lesions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Density Conservation Agents / therapeutic use
  • Bone and Bones / drug effects
  • Bone and Bones / pathology*
  • Cell Line
  • Cell Transdifferentiation
  • Dendritic Cells / pathology*
  • Diphosphonates / therapeutic use
  • Disease Models, Animal
  • Histiocytosis, Langerhans-Cell / complications
  • Histiocytosis, Langerhans-Cell / pathology*
  • Humans
  • Langerhans Cells / pathology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Osteoclasts / pathology
  • Osteolysis / complications
  • Osteolysis / pathology*
  • Osteolysis / prevention & control
  • Osteoprotegerin / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Osteoprotegerin

Grants and funding

The work was supported by grants from the Swiss National Science Foundation to HAO and PS, the Histiocytosis Research Trust to HAO and FIRB RBAP11H2R9-OO4 and Progetto Invecchiamento to PV.